According to Dr. Hilary Cass, author of a pivotal review on pediatric gender medicine, a planned clinical trial for puberty-suppressing drugs is necessary to prevent further harm to gender-questioning youth. Dr. Cass asserted that failing to conduct this research would likely result in more negative outcomes for children than proceeding with the study.
The Pathways trial, managed by King’s College London, faces scrutiny from critics over its inclusion of children as young as 11. However, researchers have implemented strict safety protocols to address these concerns. Dr. Cass, who initially suggested the study due to a lack of solid evidence regarding such medications, believes public fears about the drugs’ specific risks are currently speculative.
The trial will track the emotional, physical, and cognitive development of participants, including bone health and fertility, to determine if the drugs are beneficial. Dr. Cass warned that without a structured trial, youth might seek medication through hazardous, unregulated channels. She noted that some children currently access irreversible hormones like testosterone prematurely, and argued that blockers could provide a necessary pause for therapeutic intervention.
Health Secretary James Murray stated that while the issue is complex, he supports relying on clinical evidence and has received strong assurances regarding participant safeguards. Although the trial was paused earlier this year due to age-related concerns, recruitment is scheduled to begin in August, pending ongoing legal challenges from groups like the Bayswater Support Group, who question the ethics and informed consent protocols of the study. Meanwhile, TransActual’s Chay Brown has encouraged broader access to care, and the Conservative party is seeking a parliamentary vote on the matter.
